Trial · NCT05818137
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | Vertigo | Ear and labyrinth disorders | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | Diarrhoea | Gastrointestinal disorders | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | Malaise | General disorders | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | Malaise | General disorders | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | Pyrexia | General disorders | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | Pyrexia | General disorders | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | COVID-19 | Infections and infestations | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | COVID-19 | Infections and infestations | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | Nasopharyngitis | Infections and infestations | Sotatercept - Primary Treatment Period | 14 | 46 | 15 |
| other | Nasopharyngitis | Infections and infestations | Sotatercept - Extension Treatment Period | 7 | 45 | 8 |
| other | Haemoglobin increased | Investigations | Sotatercept - Primary Treatment Period | 8 | 46 | 8 |
| other | Haemoglobin increased | Investigations | Sotatercept - Extension Treatment Period | 3 | 45 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Sotatercept - Primary Treatment Period | 3 | 46 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Sotatercept - Extension Treatment Period | 0 | 45 | 0 |
| other | Headache | Nervous system disorders | Sotatercept - Primary Treatment Period | 10 | 46 | 10 |
| other | Headache | Nervous system disorders | Sotatercept - Extension Treatment Period | 1 | 45 | 1 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Sotatercept - Primary Treatment Period | 8 | 46 | 12 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Sotatercept - Extension Treatment Period | 5 | 45 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05818137/events